46 results
8-K
EX-99.1
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its
8-K
EX-99.1
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
conditions on Immunovant’s business operations and supply chain, including its clinical development plans and timelines; Immunovant’s business is heavily
8-K
EX-99.1
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
macroeconomic conditions on Immunovant’s business operations and supply chain, including its clinical development plans and timelines; Immunovant’s business
S-3ASR
IMVT
Immunovant Inc
9 Nov 23
Automatic shelf registration
8:49am
tensions and adverse macroeconomic conditions, on our business, operations and supply chain, including the potential impact on our clinical trial plans … factors, such as the COVID-19 pandemic, geopolitical tensions and adverse macroeconomic conditions, on our business, operations and supply chain
8-K
EX-99.1
fcouqcson
9 Nov 23
Results of Operations and Financial Condition
7:06am
424B5
3tqukbg bamh1pjri
29 Sep 23
Prospectus supplement for primary offering
4:48pm
424B5
16dg2cg7b q0
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
ivtr 0jl0
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
EX-99.1
nmcewvxy mqb
10 Aug 23
Results of Operations and Financial Condition
7:10am
8-K
EX-99.1
rj6sqazm fr19
22 May 23
Results of Operations and Financial Condition
7:03am
424B5
mqdpxj1gv6zzszx
5 Oct 22
Prospectus supplement for primary offering
4:43pm